H Vollbach1, S Brandt1, G Lahr2, C Denzer1, J von Schnurbein1, K-M Debatin3, M Wabitsch1. 1. Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany. 2. Molecular Diagnostics Laboratories, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany. 3. Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Abstract
OBJECTIVE: We aimed to determine the prevalence of melanocortin-4 receptor (MC4R) variants in a large German cohort of children with obesity in a pediatric outpatient clinic and to ascertain whether there is a specific phenotype associated with loss-of-function variants as previously reported. STUDY DESIGN: Eight hundred and ninety-nine patients from our pediatric obesity clinic were screened for MC4R variants by DNA sequencing after PCR amplification. Retrospective statistical analysis of anthropometric and metabolic characteristics was performed, comparing patients with and without MC4R variants across the entire cohort (n=586) as well as in case-control analysis using patients with common sequence MC4R individually matched for age, sex and body mass index standard deviation score (SDS) (n=11 case-control pairs). RESULTS: We identified heterozygous variants within the coding region of the MC4R gene in n=22 (2.45%) patients. Fourteen (1.56%) had a variant that impaired receptor function. One new frameshift (p.F152Sfs), an yet unpublished nonsense mutation (p.Q156X) and one nonsynonymous variation (p.V65E) described in the Mouse Genome Database were detected. Across the whole cohort, at all ages, mean height SDS in subjects with impaired receptor function was higher than in patients with common sequence MC4R. In matched individuals, this trend persisted (8 of the 11 pairs) within the case-control setting. No differences were found regarding metabolic characteristics. CONCLUSIONS: The observed prevalence of mutations causing impaired receptor function in this large cohort is comparable to other pediatric cohorts. MC4R deficiency tends to lead to a taller stature, confirming previous clinical reports. The association of MC4R mutations with a distinct phenotype concerning metabolic characteristics remains questionable.
OBJECTIVE: We aimed to determine the prevalence of melanocortin-4 receptor (MC4R) variants in a large German cohort of children with obesity in a pediatric outpatient clinic and to ascertain whether there is a specific phenotype associated with loss-of-function variants as previously reported. STUDY DESIGN: Eight hundred and ninety-nine patients from our pediatric obesity clinic were screened for MC4R variants by DNA sequencing after PCR amplification. Retrospective statistical analysis of anthropometric and metabolic characteristics was performed, comparing patients with and without MC4R variants across the entire cohort (n=586) as well as in case-control analysis using patients with common sequence MC4R individually matched for age, sex and body mass index standard deviation score (SDS) (n=11 case-control pairs). RESULTS: We identified heterozygous variants within the coding region of the MC4R gene in n=22 (2.45%) patients. Fourteen (1.56%) had a variant that impaired receptor function. One new frameshift (p.F152Sfs), an yet unpublished nonsense mutation (p.Q156X) and one nonsynonymous variation (p.V65E) described in the Mouse Genome Database were detected. Across the whole cohort, at all ages, mean height SDS in subjects with impaired receptor function was higher than in patients with common sequence MC4R. In matched individuals, this trend persisted (8 of the 11 pairs) within the case-control setting. No differences were found regarding metabolic characteristics. CONCLUSIONS: The observed prevalence of mutations causing impaired receptor function in this large cohort is comparable to other pediatric cohorts. MC4R deficiency tends to lead to a taller stature, confirming previous clinical reports. The association of MC4R mutations with a distinct phenotype concerning metabolic characteristics remains questionable.
Authors: Tamas L Horvath; Beatrix Sarman; Cristina García-Cáceres; Pablo J Enriori; Peter Sotonyi; Marya Shanabrough; Erzsebet Borok; Jesus Argente; Julie A Chowen; Diego Perez-Tilve; Paul T Pfluger; Hella S Brönneke; Barry E Levin; Sabrina Diano; Michael A Cowley; Matthias H Tschöp Journal: Proc Natl Acad Sci U S A Date: 2010-08-02 Impact factor: 11.205
Authors: Linda van den Berg; Olivier van Beekum; Peter Heutink; Bram A Felius; Monique P M van de Heijning; Stefan Strijbis; Rosalina van Spaendonk; Daniela Piancatelli; Keith M Garner; Rajae El Aouad; Erik Sistermans; Roger A H Adan; Henriette A Delemarre-van de Waal Journal: Obesity (Silver Spring) Date: 2010-10-21 Impact factor: 5.002
Authors: D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison Journal: Nature Date: 1994-10-27 Impact factor: 49.962
Authors: Maria Caterina De Rosa; Alessandra Chesi; Shana McCormack; Justin Zhou; Benjamin Weaver; Molly McDonald; Sinead Christensen; Kalle Liimatta; Michael Rosenbaum; Hakon Hakonarson; Claudia A Doege; Struan F A Grant; Joel N Hirschhorn; Vidhu V Thaker Journal: J Clin Endocrinol Metab Date: 2019-07-01 Impact factor: 5.958
Authors: Lotte Kleinendorst; Ozair Abawi; Bibian van der Voorn; Mieke H T M Jongejan; Annelies E Brandsma; Jenny A Visser; Elisabeth F C van Rossum; Bert van der Zwaag; Mariëlle Alders; Elles M J Boon; Mieke M van Haelst; Erica L T van den Akker Journal: PLoS One Date: 2020-05-08 Impact factor: 3.240
Authors: Eline S van der Valk; Erica L T van den Akker; Mesut Savas; Lotte Kleinendorst; Jenny A Visser; Mieke M Van Haelst; Arya M Sharma; Elisabeth F C van Rossum Journal: Obes Rev Date: 2019-03-01 Impact factor: 9.213